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Abstract  Because  of  its  prevalence,  breast  cancer  is  a  major  public  health  problem  although
its prognosis  has  improved  as  a  result  of  early  screening  and  improvement  in  treatments.  We
now no  longer  refer  to  breast  cancer  in  the  singular,  but  to  breast  cancers,  which  have  differentNeoadjuvant;
Targeted  therapy;
Triple  negative
prognoses  and  treatments  depending  on  their  molecular  proﬁle.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Epidemiological ﬁndings, a few ﬁgures
Because  of  its  prevalence,  breast  cancer  is  still  a  major  public  health  problem.  It  has  been
estimated  that  53,000  women  suffered  from  it  in  France  in  2012  [1].  Incidence  of  breast
cancer  in  France  and  that  it  killed  more  than  11,000  people.  Its  incidence  is  low  under  the
age  of  30-years-old  and  then  increases  up  to  the  age  of  60—69-years-old  when  it  is  over
320  per  100,000  women  per  year.  Rates  fall  slightly  after  the  age  of  85-years-old  (245  per
100,000).
These  ﬁgures  make  breast  cancer  the  leading  cause  of  cancer  deaths  in  women  with  an
estimated  ﬁgure  for  2012  of  11,289  deaths  in  France.  Death  rates  increase  with  age  from
10/100,000  women  between  35  and  40-years-old  to  80/100,000  at  around  65-years-old,
102/100,000  between  70  and  74-years-old  and  245  per  100,000  over  85-years-old.  Of  these
11,289  women  who  died  from  breast  cancer  in  France  1075  were  under  40-years-old  and
4113  were  under  65-years-old  [2].  These  ﬁgures  highlight  the  magnitude  of  the  problem
in  postmenopausal  women,  particularly  as  the  mortality  rate  is  continuing  to  increase,
mostly  in  elderly  women.  Five-year  survival  has  been  estimated  to  be  86%,  compared  to  a
10-year  rate  of  76%.
E-mail address: marc.espie@sls.aphp.fr
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ocoregional treatments
urgery  remains  the  main  treatment  for  breast  cancer.
hanges  in  surgery  have  included  a  reduction  in  the  indi-
ations  for  mastectomy  (which  is  still  however  occasionally
ecessary)  and  an  increase  of  conservative  treatments,  par-
icularly  incorporating  plastic  surgery  techniques  into  breast
urgery  (oncoplasty),  which  allows  more  bulky  tumors  to  be
xcised.  Initial  (neoadjuvant)  chemotherapy  can  also  make
urgery  more  conservative  by  reducing  tumor  volume.  In  par-
llel  to  this  increase  in  conservative  treatment,  the  ‘sentinel
ymph  node’  technique  has  emerged,  which  allows  the  initial
xillary  lymph  nodes,  which  are  most  likely  to  be  diseased,
o  be  removed  without  carrying  out  axillary  curettage  if
hese  lymph  nodes  are  not  invaded.  This  technique  therefore
elps  to  reduce  the  adverse  effects  of  axillary  curettage,
nd  particularly  the  risks  of  lymphedema.  It  requires  pre-
perative  injection  of  a  blue  dye  and  a  radioactive  isotope
round  the  tumor  or  areola.  This  dual  technique  helps  to
educe  the  risk  of  false  negative  results  [3].
Treatment  intensity  may  also  be  reducing  in  radiotherapy.
n  conservative  treatment,  the  general  rule  is  to  irradiate
he  whole  breast  with  additional  radiotherapy  to  the  tumor
ed  and  irradiation  of  the  lymph  node  regions  if  these  are
iseased.  Changes  in  radiotherapy  dose  and  methods  are
eing  studied  in  some  patients  and  partial  breast  irradia-
ion  is  occasionally  being  offered  (elderly  patients  and  small,
elatively  non-aggressive  tumors)  [4].
Reconstruction  surgery  has  also  advanced  in  patients  with
astectomy,  with  the  development  of  same  stage  recon-
truction  techniques  although  these  are  not  always  possible
nd  need  patients  to  fully  understand  that  their  breast  will
ot  return  to  what  it  was  before,  together  with  advances  in
ucocutaneous  and  skin  and  fatty  tissue  ﬂaps  (DIEP1) [5].
rognostic indicators for breast cancer
nd poor prognostic indicators for
esponse to treatments
n  addition  to  the  conventional  prognostic  indicators  (size
f  tumor,  lymph  node  invasion,  grade  and  age),  in  recent
ears,  hormone-receptors  (estrogens  and  progesterone)  and
verexpression  of  HER2  (or  CerbB2)  (an  epithelial  growth
actor)  reﬂecting  self-encasement  of  the  tumor  have  been
dded.  The  Ki67  test  is  also  useful  as  this  can  quantify
ellular  proliferation  (the  Ki-67  labeling  index  represents
he  percentage  of  nuclei  stained  by  the  Ki-67  antibody).
enomic  tests  are  currently  being  developed  with  the  aim
f  analyzing  each  tumor  to  ‘predict’  its  prognosis  and  also
o  determine  whether  adjuvant  chemotherapy  or  hormone
herapy  are  or  are  not  essential.  The  concept  of  breast  can-
er  is  now  increasingly  being  broken  down  and  several  tumor
ubtypes  have  been  identiﬁed:
luminal  A  cancers:  these  are  breast  cancers  which  carry
a  good  prognosis,  progress  slowly  and  strongly  express
estrogen  and  progesterone  receptors.  They  do  not  overex-
press  HER2  and  are  therefore  ER+++,  PR+++,  and  CerbB2
1 DIEP: deep inferior epigastric.
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negative.  These  are  the  relatively  non-proliferative  hor-
mone  dependent  tumors,  which  often  do  not  require
chemotherapy,  particularly  if  the  Ki67  index  is  under  10%;
luminal  B  cancers:  these  carry  a  less  good  prognosis
than  luminal  A,  are  less  hormone-sensitive,  and  often
have  a  higher  Ki67  index.  Some  may  be  associated  with
HER2  overexpression  and  the  combination  of  chemother-
apy  and  hormone  therapy  is  often  required  together  with
trastuzumab  (Herceptin)  if  HER2  is  overexpressed;
HER2  cancers:  these  are  aggressive  breast  cancers,  which
carry  a  poor  prognosis.  They  are  estrogen  and  proges-
terone  receptor  negative  and  their  HER2  overexpression
is  graded  +++.  These  cancers  require  chemotherapy  com-
bined  with  trastuzumab  which  has  changed  their  poor
prognosis;
‘triple  negative’  cancers:  these  are  also  poor  prognosis
cancers,  which  are  completely  undifferentiated  and  are
estrogen  and  progesterone  receptor  negative.  They  do  not
overexpress  HER2  (ER−, PR−,  HER2−) (Figs.  1  and  2).
There  is  other  less  common  subtypes,  which  are  still
eing  studied  and  gene  analysis  (genomics)  is  developing.
his  can  be  used  to  characterize  tumor  genes,  and  to  test  for
mpliﬁcations,  mutations  and  the  level  of  expression  (gain
r  loss)  of  a  given  gene.  Apart  from  the  genes  involved  in
ormone-receptors  and  HER2  expression,  other  genes  are
eing  examined  which  are  involved  in  invasion,  and  inter-
ctions  with  the  tumor  stroma,  etc.  It  is  hoped  that  by
uiding  treatment  and  predicting  sensitivity  to  treatments
n  attempt  can  be  made  to  individualize  them  to  avoid
hemotherapy,  which  is  of  no  beneﬁt  for  one  person  whereas
t  may  be  essential  for  another.  Several  tests  have  been
eveloped:  the  Mammaprint  which  is  a test  performed  from
 DNA  probe  which  shows  the  expression  of  70  genes,  Onco-
ype  DX  which  shows  21  genes,  and  genomic  grade,  which  is
n  analysis  of  the  expression  of  97  genes  on  frozen  sam-
les,  etc.  These  tests  incorporate  a  number  of  different
enes  although,  overall  and  apart  from  hormone  and  HER2
eceptors,  these  are  mostly  genes  involved  in  proliferation.
hey  have  not  as  yet  been  shown  to  be  more  effective  than
onventional  immune-histochemical  indicators.  Prospective
tudies  are  therefore  ongoing  and  we  should  have  an  answer
o  the  question  of  their  actual  utility  in  a  few  years.  They
ave  however  been  validated  in  retrospective  studies  and
o  identify  groups  with  a  good  or  bad  prognosis.  They  do
ot  have  marketing  authorization  in  France  pending  their
ossible  validation  in  the  ongoing  prospective  studies.
djuvant treatments: chemotherapy,
ormone therapy, targeted therapies
hanges in chemotherapy
n  the  1980s,  chemotherapy  was  often  restricted  to  patients
hose  tumors  were  associated  with  lymph  node  invasion,
lthough  metastases  were  found  for  20  to  30%  of  tumors
hen  lymph  node  invasion  was  not  present.  It  was  there-
ore  extended  to  forms  of  the  disease  without  lymph  nodes
nvasion,  which  carried  a  poor  prognosis  (large  size,  grade
I  or  III,  vascular  emboli+,  or  negative  hormone-receptors).
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Figure 1. Mammography (a,b). Triple negative breast cancer.
Images provided by Martine Boisserie-Lacroix, Bergonié Institute.
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on  sexual  function,  and  cognitive  disorders,  etc.  These  areFigure 2. Triple negative cancer. MR (magnetic resonance)
appearances: ring-shaped enhancement.
In  parallel,  the  type  of  chemotherapy  has  changed  from  a
reference  protocol  known  as  CMF2 to  FAC  or  FEC3 regimens
including  anthracyclines  and  then  to  regimens  including
taxanes4 [6],  as  a  result  of  the  randomized  trials  which  have
shown  the  beneﬁt  of  these  new  molecules  [7].
Targeted  therapies
In  2005,  trastuzumab  (Herceptin)  was  proposed  as  an  adju-
vant  therapy  because  of  its  effectiveness  in  metastatic
disease.  This  monoclonal  antibody  blocks  the  HER2  recep-
tor  and  therefore  interrupts  the  cascade  leading  to  cellular
proliferation.  As  a  result  of  trastuzumab,  cancers  which
overexpress  HER2  no  longer  carry  such  a  poor  prognosis.
2 CMF: Cyclophosphamide, Methotrexate, 5-Fluorouracil.
3 FAC: 5-Fluorouracil, Doxorubicin (Adriamycin), Cyclophos-
phamide; FEC: 5-Fluorouracil, Epidoxorubicin, Cyclophosphamide.
4 Taxanes: Docetaxel (Taxotere), Paclitaxel (Taxol).
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(rastuzumab  is  currently  administered  IV  every  3  weeks  for
 year  and  is  always  combined  with  chemotherapy.  A  subcu-
aneous  form  is  currently  being  developed  as  are  many  other
olecules,  which  target  this  pathway.  As  a  result  of  the  use
f  this  molecule,  the  relative  risk  of  relapse  has  fallen  by
pproximately  50%  [8].
This  molecule  requires  the  LVEF5 to  be  monitored  by
chocardiography  or  myocardial  scintigraphy  as  it  can  often
roduce  a  usually  transient  decline.
urrent  reference  treatments
hemotherapy  generally  involving  a  sequential  combination
f  anthracyclines  and  taxanes  are  offered  for  N+  or  N−
ancers  with  poor  prognostic  indicators  which  do  not  overex-
ress  HER2:  3  FEC  100  3  Docetaxel,  4  EC  4  Docetaxel,  3  FEC
00  12  weekly  Paclitaxel.  . . or  a  simultaneous  combination
ith  6  TAC.
For  cancers  which  overexpress  HER2,  as  soon  as  they
re  over  5 mm  in  size  a  combination  of  chemotherapy
nd  trastuzumab  is  often  proposed:  3  FEC  100  +  3  Tax-
tere  +  Herceptin  for  a  year  started  at  the  same  time  as
rastuzumab,  6  TCH  particularly  if  anthracyclines  are  con-
raindicated,  4EC  4  TH6.  .  .
oxicities
he  immediate  toxicities  of  chemotherapy  are  well  known
nd  include  alopecia,  nausea/vomiting,  fatigue,  risk  of  fever
nd  infections,  muscle  pains,  paresthesiae,  repercussionsommon  but  reversible.  The  late  toxicities  include  car-
iotoxicity  and  occasional  chemo-induced  leukemia  (1  to  2%)
lthough  these  toxicities  are  not  always  reversible  (heart)
5 LVEF: left ventricular ejection fraction.
6 TAC: Docetaxel (Taxotere), Doxorubicin (Adriamycin), Cyclo-
hosphamide, EC: Epirubicin Cyclophosphamide, TCH: Docetaxel
taxotere), Carboplatin, Herceptin.
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r  curable  (leukemia).  The  risk  of  chemotherapy-induced
enopause  and  therefore  sterility  should  not  be  forgotten
n  young  women  and  should  be  discussed  and  planned  for
efore  treatment  is  started.
ormone therapy
ive  years  of  hormone  therapy  has  been  shown  to  provide
eneﬁt  when  offered  to  any  patient  with  a  hormone-
eceptor-positive  tumor.  The  treatments  vary  depending  on
enopausal  status.  In  the  pre-menopausal  period,  the  refer-
nce  molecule  is  tamoxifen  whereas  in  the  postmenopausal
eriod,  the  anti-aromatases  are  preferred.  It  is  occasionally
ossible  to  offer  a  sequence  of  tamoxifen  for  2  or  3  years
ollowed  by  anti-aromatases  during  the  peri-menopausal
eriod.  An  extension  of  treatment  beyond  5  years  can  be
ffered  in  some  cases  particularly  in  patients  at  high  risk  of
ecurrence  (N+)  [9,10].
It is  essential  to  be  certain  about  a  woman’s  menopausal
tatus  as  the  aromatase  inhibitors  are  ineffective  before  the
enopause  and  it  is  important  to  be  aware  that  amenor-
hea  is  not  synonymous  with  the  menopause.  A  minimum  of
 years  of  amenorrhea  is  required  in  a  young  woman  before
eferring  to  the  menopause.  Hormone  measurements  are  of
imited  use  as  they  only  reﬂect  the  situation  on  the  day  when
he  blood  sample  was  taken.
oxicities
he  most  common  adverse  effects  reported  by  patients  on
amoxifen  are  hot  ﬂushes,  weakness  or  a  tendency  towards
epression,  weight  gain  and  leucorrhea.  Very  rare  but  poten-
ially  serious  toxic  reactions  are  due  to  thrombo-embolic
vents  and  endometrial  cancer.  Excess  cataracts  develop
nd  occasional  cases  of  hepatitis  and  thrombocytopenia
re  also  seen.  Patients  receiving  aromatase  inhibitors  com-
lain  of  arthralgia,  vaginal  dryness  and  reduced  libido.
ypercholesterolemia  may  develop  particularly  involving
DL-cholesterol.  Bone  mineral  density  is  reduced  with  an
ncreased  fracture  rate  and  an  increase  in  coronary  artery
vents  [11].
The  choice  between  these  molecules  should  also  there-
ore  take  account  of  each  patient’s  individual  risk  proﬁle.
eoadjuvant therapies
hese  should  be  offered  routinely  to  patients  who  have  an
nﬂammatory  cancer  and  to  many  patients  with  rapidly  pro-
ressing  tumors,  and  to  make  tumors,  which  were  inoperable
t  the  time  of  diagnosis  (T4)  amenable  to  surgery,  and  to  per-
it  conservative  surgery  if  this  was  not  possible  at  the  time
f  diagnosis  (bulky  T2  and  T3)7.  Neoadjuvant  chemotherapy
oes  not  change  survival  compared  to  adjuvant  chemother-
py  although  achieving  a  complete  histological  response
fter  chemotherapy  does  have  a  positive  impact  on  survival.
he  histological  response  to  chemotherapy  differs  depend-
ng  on  the  molecular  subtypes  described  above,  the  more
ggressive  tumors  being  the  most  chemosensitive  [12].
7 T2: tumor between 2 and 5 cm size; T3: tumor over 5 cm size;
4: tumor ﬁxed to the deep planes and/or to the skin.
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Depending  on  the  situation,  a  complete  histological
esponse  is  achieved  in  15  to  40%  of  patients.  The  propor-
ion  of  conservative  breast  surgery  has  increased  for  T2  and
3  tumors  and  may  be  achievable  in  approximately  75%  of
ases.
ew treatments
he  major  advances  have  mostly  been  made  for  tumors  over-
xpressing  HER2.  Many  protocols  are  currently  used  with  a
ombination  of  two  targeted  therapies  and  chemotherapy
nd  have  produced  good  results  in  both  the  neoadjuvant
nd  metastatic  situation.  In  the  metastatic  stage,  the  com-
ination  of  trastuzumab  +  pertuzumab  (another  anti-HER2
onoclonal  antibody  with  a  different  binding  site)  does  bet-
er  than  trastuzumab  alone  [13].
The  same  results  have  been  shown  in  the  neoadjuvant
ituation  with  a  combination  of  lapatinib  (an  anti-tyrosine
inase)  and  trastuzumab  [14].
It  has  been  possible  to  design  a  molecule,  which  combines
oth  chemotherapy  and  targeted  therapy,  trastuzumab  and
aytansine.  The  term  used  to  describe  this  is  vectorized
hemotherapy,  in  which  the  chemotherapy  is  carried  to  and
eleased  only  in  the  tumor  cells.  This  is  both  effective  and
ess  toxic  [15].
In  HR+  hormone  dependent  cancers,  patients  with  metas-
asis  cease  to  respond  to  hormone  therapy  after  treatment
or  8  to  12  months.  Molecules  are  being  developed  to
reverse’  its  resistance.  Everolimus  (Aﬁnitor)  has  been
ested  in  this  situation  and  showing  to  be  effective  [16].
onclusion
he  management  of  patients  suffering  from  breast  cancer  is
ecoming  complicated  and  we  are  moving  gradually  from  the
off  the  peg’  to  the  ‘tailor-made’.  Considerable  advances
ave  been  achieved  over  the  last  30  years  in  the  manage-
ent  of  these  women  and  this  is  leading  to  higher  cure
ates.
TAKE-HOME  MESSAGES
• The  following  types  of  cancers  can  be  distinguished:
◦ luminal  A:  highly  positive  ER  and  PR
◦ luminal  B:  +ER  ±  PR,  high  Ki67,  occasionally  HER2
+++
◦ HER2  +++  ER  neg,  PR  neg
◦ triple  negative:  ER  negative,  PR  negative,  HER2
negative
• Advances  in  treatment  will  involve  better  indivi-
dualizing  therapies  through  genomics  and  pharma-
cogenomics.isclosure of interest
he  author  declares  that  he  has  no  conﬂicts  of  interest  con-
erning  this  article.
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